報價延遲最少15分鐘:2026/04/16 00:35 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
6 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.34/-0.39
|
|
企業價值
1.42B
|
| 資產負債 |
|
每股賬面淨值
0.86
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
9.77M
|
|
每股收益
0.03
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system. |
